BMH-22

• Description:

  BMH-22, a benzonaphthyridin, is a RNA polymerase I (Pol I) transcription inhibitor independent of p53 function. BMH-22 causes reorganization of nucleolar marker proteins consistent with segregation of the nucleolus. BMH-22 destabilizes RPA194 in a proteasome-dependent manner and inhibits nascent rRNA synthesis and expression of the 45S rRNA precursor. BMH-22 shows potent anticancer activity across many tumor types[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H314

• Target:

  DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bmh-22.html

• Purity:

  98.85

• Solubility:

  DMSO : 4.17 mg/mL (ultrasonic)

• Smiles:

  CC1=C2N=C3N=C(C=C(C3=C(C2=CC(C)=C1)N)C)C

• Molecular Formula:

  C16H17N3

• Molecular Weight:

  251.33

• Precautions:

  H314

• References & Citations:

  [1]RPA194, rRNA synthesis, 45S Rrna, anticancer Karita Peltonen, et al. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol Cancer Ther. 2014 Nov;13 (11) :2537-46.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [309726-06-5]